Central hypertensive actions of angiotensin I, II and III in conscious rats. 1979

K Kondo, and T Okuno, and T Eguchi, and T Yasui, and R Nakamura, and T Saruta

The effects of intracerebroventricular administrations of three natural angiotensins, angiotensin I (ANG I 3.8 X 10-11-9.4 X10-10 mol/kg body weight), II (9.6 X 10-12-2.4 X 10-10 mol/kg body weight) and III (2.7 X 10-10 2.5 X 10-9 mol/kg body weight) on systemic blood pressure were investigated in conscious rats. Angiotensin II (ANG II), ANG I and angiotensin III (ANG III), increased blood pressure in a dose-related manner. The order of potency of angiotensins was ANG II greater than ANG I greater than ANG III. The intraventricular administration of a converting enzyme inhibitor (SQ 14225, 6.9 X10-8 mol/kg) abolished the central effect of ANG I, while an angiotensin II analogue ([Sar1-Ala8]ANG II, 1.1 X 10-8 mol/kg) administered intraventricularly inhibited the central pressor effects of these three angiotensins. These results suggest that ANG II is a main mediator of the renin-angiotensin system in the central nervous system.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007276 Injections, Intraventricular Injections into the cerebral ventricles. Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D008297 Male Males
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000803 Angiotensin I A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000805 Angiotensin III A heptapeptide formed from ANGIOTENSIN II after the removal of an amino acid at the N-terminal by AMINOPEPTIDASE A. Angiotensin III has the same efficacy as ANGIOTENSIN II in promoting ALDOSTERONE secretion and modifying renal blood flow, but less vasopressor activity (about 40%). Des-Asp Angiotensin II,Des-Aspartyl-Angiotensin II,Angiotensin II, Des-Asp,Des Asp Angiotensin II,Des Aspartyl Angiotensin II
D000809 Angiotensins Oligopeptides which are important in the regulation of blood pressure (VASOCONSTRICTION) and fluid homeostasis via the RENIN-ANGIOTENSIN SYSTEM. These include angiotensins derived naturally from precursor ANGIOTENSINOGEN, and those synthesized. Angiotensin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

K Kondo, and T Okuno, and T Eguchi, and T Yasui, and R Nakamura, and T Saruta
October 1992, The American journal of physiology,
K Kondo, and T Okuno, and T Eguchi, and T Yasui, and R Nakamura, and T Saruta
November 2005, Clinical and experimental hypertension (New York, N.Y. : 1993),
K Kondo, and T Okuno, and T Eguchi, and T Yasui, and R Nakamura, and T Saruta
January 1974, Acta physiologica latino americana,
K Kondo, and T Okuno, and T Eguchi, and T Yasui, and R Nakamura, and T Saruta
May 1989, Brain research,
K Kondo, and T Okuno, and T Eguchi, and T Yasui, and R Nakamura, and T Saruta
April 1977, The American journal of physiology,
K Kondo, and T Okuno, and T Eguchi, and T Yasui, and R Nakamura, and T Saruta
June 1998, Journal of cardiovascular pharmacology,
K Kondo, and T Okuno, and T Eguchi, and T Yasui, and R Nakamura, and T Saruta
June 2007, Hypertension (Dallas, Tex. : 1979),
K Kondo, and T Okuno, and T Eguchi, and T Yasui, and R Nakamura, and T Saruta
June 1995, Hypertension (Dallas, Tex. : 1979),
K Kondo, and T Okuno, and T Eguchi, and T Yasui, and R Nakamura, and T Saruta
August 2004, Regulatory peptides,
K Kondo, and T Okuno, and T Eguchi, and T Yasui, and R Nakamura, and T Saruta
January 1984, The American journal of physiology,
Copied contents to your clipboard!